Over the last 7 days, the United States market has remained flat, yet it has seen an impressive 18% increase over the past year with earnings expected to grow by 17% annually in the coming years. In this context of steady growth and optimistic projections, identifying undervalued stocks can offer potential opportunities for investors seeking to capitalize on discrepancies between current stock prices and their intrinsic values.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Xeris Biopharma Holdings (XERS) | $8.44 | $16.02 | 47.3% |
| Vertex (VERX) | $14.16 | $27.87 | 49.2% |
| Natera (NTRA) | $321.96 | $610.40 | 47.3% |
| Mobileye Global (MBLY) | $8.53 | $16.41 | 48% |
| Lumentum Holdings (LITE) | $914.76 | $1770.06 | 48.3% |
| Huntington Bancshares (HBAN) | $16.685 | $33.34 | 50% |
| Goosehead Insurance (GSHD) | $68.65 | $134.62 | 49% |
| Coherent (COHR) | $277.83 | $525.48 | 47.1% |
| Boeing (BA) | $207.78 | $393.65 | 47.2% |
| Alerus Financial (ALRS) | $32.90 | $63.02 | 47.8% |
Let's dive into some prime choices out of the screener.
Ligand Pharmaceuticals (LGND)
Overview: Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that develops and licenses biopharmaceutical assets globally, with a market cap of approximately $5.67 billion.
Operations: The company generates revenue of $290.54 million from the development and licensing of biopharmaceutical assets worldwide.
Estimated Discount To Fair Value: 33.5%
Ligand Pharmaceuticals, trading at US$284.1, is significantly undervalued based on discounted cash flow estimates of US$427.46. Despite a recent drop from several indices, its revenue and earnings are forecast to grow faster than the broader U.S. market at 17.3% and 19.5% annually, respectively. Recent earnings showed substantial improvement with net income rising to US$48.51 million in Q2 2026 from US$4.85 million a year ago, supporting its undervaluation thesis based on cash flows.
- In light of our recent growth report, it seems possible that Ligand Pharmaceuticals' financial performance will exceed current levels.
- Click here to discover the nuances of Ligand Pharmaceuticals with our detailed financial health report.
Capital Southwest (CSWC)
Overview: Capital Southwest Corporation is a business development company with a market cap of $1.62 billion.
Operations: The company generates revenue primarily through its investment segment, which amounts to $237.21 million.
Estimated Discount To Fair Value: 14.0%
Capital Southwest, trading at US$25.57, is undervalued based on discounted cash flow estimates of US$29.75. Despite being dropped from the NASDAQ Composite Index, its earnings are forecast to grow significantly at 24% annually, outpacing the U.S. market's growth rate of 17%. However, interest payments and dividends remain poorly covered by earnings or free cash flows. Recent revenue growth to US$61.05 million in Q1 2026 reflects a positive trend amidst these challenges.
- Our comprehensive growth report raises the possibility that Capital Southwest is poised for substantial financial growth.
- Unlock comprehensive insights into our analysis of Capital Southwest stock in this financial health report.
Jabil (JBL)
Overview: Jabil Inc. offers engineering, manufacturing, and supply chain solutions globally with a market cap of approximately $31.59 billion.
Operations: Jabil's revenue is derived from three main segments: Regulated Industries at $12.41 billion, Intelligent Infrastructure at $15.79 billion, and Connected Living and Digital Commerce at $5.39 billion.
Estimated Discount To Fair Value: 40.1%
Jabil is trading at US$305.26, significantly undervalued against its estimated future cash flow value of US$509.71. Despite high debt levels, the company demonstrates robust financial health with a forecasted return on equity of 82.2% in three years and expected annual profit growth of 31%, surpassing the U.S. market average. Recent expansions in Penang and Pune enhance operational capacity, while strategic alliances like the one with Adani Enterprises bolster its global manufacturing footprint.
- Our growth report here indicates Jabil may be poised for an improving outlook.
- Delve into the full analysis health report here for a deeper understanding of Jabil.
Taking Advantage
- Get an in-depth perspective on all 148 Undervalued US Stocks Based On Cash Flows by using our screener here.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Seeking Other Investments?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com